Migraine: Evidence-Based Clinical Guidance

Migraine is a neurological disorder characterized by recurrent, severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. Attacks can last 4–72 hours and significantly impair daily functioning.

Moderate-quality evidenceLast reviewed: 2026Guideline year: 2024Evidence: v1

Evidence Overview

Migraine is supported by moderate-quality guideline-supported evidence. Current authority mapping includes 0 diagnostic tests and 8 treatment options, enabling structured evidence-based clinical guidance.

Guideline Summary

  • •Clinical guidance for Migraine emphasizes early severity assessment, comorbidity review, and risk-adjusted management decisions.
  • •Guideline workup prioritizes clinical history, examination findings, and risk stratification where dedicated test mapping is limited.
  • •Therapy is escalated stepwise, starting with Sumatriptan and Rizatriptan, then adapting to response and safety profile.

Diagnostic Evidence

  • •Diagnostic probability for Migraine is established by combining history, examination, and objective findings.
  • •When dedicated test mapping is sparse, clinicians rely on serial reassessment and targeted referral to avoid missed high-risk disease.

Treatment Evidence

First-line Therapy

  • •First-line evidence-supported options include Sumatriptan and Rizatriptan when clinically appropriate.
  • •Dose titration and treatment sequencing should follow guideline-defined efficacy and safety checkpoints.

Alternative Therapies

  • •Alternative agents include Zolmitriptan, Naratriptan, Eletriptan for intolerance, contraindication, or inadequate response.
  • •Monitoring requirements should be individualized based on age, organ function, interactions, and treatment duration.

Evidence Limitations

  • •Evidence translation for Migraine depends on patient phenotype, disease stage, and comorbidity burden.
  • •Guideline recommendations can differ by region, available diagnostics, and drug access.
  • •Current graph density is limited, so some decisions rely on broader specialty guidance rather than condition-specific comparative trials.

Clinical Importance

  • •Migraine carries meaningful clinical impact because delayed recognition can increase complications, care intensity, and recovery time.
  • •Long-term outcome optimization depends on guideline-based monitoring, adherence, and early control of progression.

Primary Sources

Guideline Bodies

  • •American Academy of Neurology (AAN)
  • •American Psychiatric Association (APA)
  • •NICE

Primary Sources

  • •Major international clinical guideline statements
  • •Systematic reviews and meta-analyses in peer-reviewed journals
  • •Condition-specific consensus pathways and safety updates

Evidence Notes

  • •Evidence often combines symptom scales, functional outcomes, and relapse prevention endpoints.
  • •Selection drivers: chronic guideline-based management; high search relevance.
  • •This authority page summarizes evidence patterns and does not replace clinician judgment.

Internal Clinical Linking

Condition Core

Migraine overview
Cluster Headache vs MigraineMeningitis vs MigraineMigraine vs Tension-Type Headache

Condition Tests

No mapped test routes for this condition.

Condition Drugs

SumatriptanRizatriptanZolmitriptanNaratriptanEletriptanFrovatriptanAlmotriptanErgotamine

Symptom Hubs

HeadacheNauseaVomiting

Need structured triage for this condition profile?

Use AI Symptom Checker for differential orientation, urgency prioritization, and next-step guidance.

Start Free AI Analysis →

Medical References

Content on this page is informed by evidence-based clinical sources including: